Portfolio

Bloodscan Biotech

Commercializing the Labyrinth microfluidic chip, engineered to efficiently isolate and purify circulating tumor cells from peripheral blood for both research and cancer diagnostic purposes.
(2026)

Enexa Bio

Enexa Bio is engineering precision small molecules for autoimmune disease, led by a biomarker-driven lupus nephritis program.
(2026)

Eradix Therapeutics

Developing Degrader-antibody conjugates for cancer treatment.
(2026)

Intero Biosystems

Developing stem-cell-derived human intestinal organoids containing functioning neurons, blood vessels, muscle, and inner lining of intestine.
(2026)

MELD Health

Commercializing an intuitive pain assessment and patient provider collaboration platform based on groundbreaking pain research using AI.
(2026)

OcularDx

Developing a vitreous biopsy needle for ophthalmic applications and an associated biorepository.
(2026)

PreSense Health

Bringing to market an early warning system to identify patients at an increased risk of deterioration. The underlying technology is a software tool called Predicting Intensive Care Transfers and other Unforeseen Events ("PICTURE").
(2026)

Qure Dynamics

Qure is developing cancer therapeutics.
(2026)

Saros Therapeutics

Developing immunotherapies for the treatment of cancer and autoimmune diseases.
(2026)

Skeletalis

Developing a novel small-molecule drug delivery system for local inhibition of disease at sites of bone degradation.
(2026)

Courage Therapeutics

Courage Therapeutics' two drug-development programs aim to address obesity and restrictive eating disorders, such as anorexia nervosa and cachexia, by targeting neural circuits in the brain known as the central melanocortin system.
(2025)

Genevi Technologies

Developing a medical device to treat stress urinary incontinence.
(2025)

Liferna Biotech

Liferna Biotech is developing a repurposed drug for scleroderma.
(2025)

MI-Hip

MI-Hip is commercializing simulators to teach physicians how to properly diagnose hip dysplasia in newborns.
(2025)

NanoOnco

NanoOnco is developing a bioabsorbable magnesium device designed to control cancer and cancer metastasis.
(2025)

Nytricx

Nytricx is developing a product using nitric oxide to prevent infection and clotting with catheters and other devices.
(2025)

Ocutheia

Ocutheia is developing a small molecule as monotherapy for dry and wet age-related macular degeneration.
(2025)

Recens Medical

Rapid precision medical cooling.
(2025)